Covered recipient · General Payments record
JASON WAYNE WILSON
Allopathic & Osteopathic Physicians Emergency Medicine
General Payments · PY2019–2025
$538,455.89
- Reported across 502 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $28,067.00 | 5 |
| Travel and Lodging | $756.93 | 3 |
| Food and Beverage | $296.24 | 6 |
| Gift | $147.17 | 2 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $20,000.00 | 1 |
| Indivior Inc. | $6,591.89 | 9 |
| Abbott Laboratories | $2,494.12 | 3 |
| MeMed US, Inc. | $147.17 | 2 |
| Ethicon US, LLC | $34.16 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $1,350.00 | 04/11/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1240564305 | CMS |
| Abbott Laboratories | $1,125.00 | 04/11/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1240564312 | CMS |
| Abbott Laboratories | $19.12 | 06/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1241045766 | CMS |
| Ethicon US, LLC | $34.16 | 05/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1173843264 | CMS |
| Gilead Sciences, Inc. | $20,000.00 | 12/31/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1234350602 | CMS |
| Indivior Inc. | $3,728.00 | 05/14/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1240504049 | CMS |
| Indivior Inc. | $1,864.00 | 05/14/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1240504053 | CMS |
| Indivior Inc. | $396.96 | 05/14/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1240504057 | CMS |
| Indivior Inc. | $56.00 | 05/14/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1240504061 | CMS |
| Indivior Inc. | $303.97 | 05/14/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1240504065 | CMS |
| Indivior Inc. | $112.79 | 05/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1240504069 | CMS |
| Indivior Inc. | $45.11 | 05/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1240504073 | CMS |
| Indivior Inc. | $39.59 | 05/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1240504077 | CMS |
| Indivior Inc. | $45.47 | 05/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1240504081 | CMS |
| MeMed US, Inc. | $57.44 | 02/02/2025 | Gift | Undisputed | 06/30/2026 | 1254402826 | CMS |
| MeMed US, Inc. | $89.73 | 02/02/2025 | Gift | Undisputed | 06/30/2026 | 1254402828 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.